Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Genedx Holdings Corp (WGS)

Genedx Holdings Corp (WGS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,158,739
  • Shares Outstanding, K 28,905
  • Annual Sales, $ 305,450 K
  • Annual Income, $ -52,290 K
  • EBIT $ 10 M
  • EBITDA $ 32 M
  • 60-Month Beta 2.01
  • Price/Sales 7.70
  • Price/Cash Flow 102.18
  • Price/Book 10.34

Options Overview Details

View History
  • Implied Volatility 62.81% (-1.43%)
  • Historical Volatility 53.98%
  • IV Percentile 30%
  • IV Rank 9.05%
  • IV High 157.37% on 04/07/25
  • IV Low 53.41% on 08/28/25
  • Expected Move (DTE 7) 2.34 (2.18%)
  • Put/Call Vol Ratio 0.59
  • Today's Volume 2,078
  • Volume Avg (30-Day) 2,661
  • Put/Call OI Ratio 1.24
  • Today's Open Interest 30,035
  • Open Int (30-Day) 24,610
  • Expected Range 105.03 to 109.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.11
  • Number of Estimates 1
  • High Estimate 0.11
  • Low Estimate 0.11
  • Prior Year 0.70
  • Growth Rate Est. (year over year) -84.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
103.01 +5.34%
on 01/15/26
144.59 -24.95%
on 12/17/25
-33.21 (-23.43%)
since 12/16/25
3-Month
103.01 +5.34%
on 01/15/26
170.87 -36.50%
on 12/02/25
-9.91 (-8.37%)
since 10/16/25
52-Week
55.17 +96.68%
on 05/08/25
170.87 -36.50%
on 12/02/25
+40.25 (+58.97%)
since 01/16/25

Most Recent Stories

More News
Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

WGS : 108.08 (-1.10%)
GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance

Expects full year 2025 revenues of $427 million, with exome and genome revenue up 54% (58% excluding a one-time 2024 benefit) Expects fourth quarter 2025...

WGS : 108.08 (-1.10%)
GeneDx and Komodo Health Partner to Build the World’s Most Complete Longitudinal Rare Disease Dataset

GeneDx’s Infinity™ will leverage insights from Komodo’s Healthcare Map ® to unlock faster health economics and outcomes research (HEOR), biopharma innovation,...

WGS : 108.08 (-1.10%)
GeneDx Announces GenomeDx Prenatalâ„¢, Expanding Industry-Leading Genomic Diagnosis Into Prenatal Care

New whole genome sequencing test delivers fast, comprehensive insights when fetal anomalies are identified, reinforcing GeneDx’s commitment to enabling precise, fast, and actionable rare disease diagnosis...

WGS : 108.08 (-1.10%)
GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care

Recognized neonatologist and payer-strategy leader joins GeneDx to expand earlier diagnosis and establish genomics as a standard of care across healthcare

WGS : 108.08 (-1.10%)
GeneDx Leads Rare Disease Genomics with Unmatched Research and Clinical Impact in 2025

Industry-leading research powered by GeneDx Infinityâ„¢ accelerates the transition of genomics from discovery to the standard of clinical care, driving better outcomes for patients across healthcare settings...

WGS : 108.08 (-1.10%)
GeneDx to Present at the J.P. Morgan 2026 Healthcare Conference

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 44th Annual J.P. Morgan Healthcare Conference...

WGS : 108.08 (-1.10%)
JAMA (Journal of the American Medical Association) Recognizes GUARDIAN Newborn Genomic Screening Study Among Its Research of the Year

Prestigious recognition underscores the impact of large-scale genomic screening in identifying serious childhood genetic conditions in conjunction with traditional newborn screening

WGS : 108.08 (-1.10%)
GeneDx to Showcase Advancements in Gene-Disease Discovery, Long-Read Sequencing and More at National Society of Genetic Counselors (NSGC) 2025 Annual Meeting

Powered by GeneDx Infinityâ„¢ with unparalleled scale and diversity, GeneDx fuels breakthrough scientific research and delivers the most precise rare disease diagnosis for patients and families

WGS : 108.08 (-1.10%)
GeneDx to Participate in Upcoming Investor Conferences

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences: ...

WGS : 108.08 (-1.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

Relative Strength is below 30%. The market is in oversold territory. Watch for a potential trend reversal.

See More Share

Business Summary

GeneDx Holdings Corp. is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation, fueled by rare disease data sets. GeneDx Holdings Corp., formerly known as Sema4 Holdings Corp., is based in STAMFORD, Conn.

See More

Key Turning Points

3rd Resistance Point 124.23
2nd Resistance Point 118.73
1st Resistance Point 114.01
Last Price 108.08
1st Support Level 103.78
2nd Support Level 98.28
3rd Support Level 93.56

See More

52-Week High 170.87
Fibonacci 61.8% 126.67
Fibonacci 50% 113.02
Last Price 108.08
Fibonacci 38.2% 99.37
52-Week Low 55.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar